World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2023 December 15; 15(12): 2049-2241





Published by Baishideng Publishing Group Inc

WÛ

Generation World Journal of Gastrointestinal Oncology

Contents

Monthly Volume 15 Number 12 December 15, 2023

EDITORIAL

2049 Dual primary gastric and colorectal cancer: A complex challenge in surgical oncology Marano L

MINIREVIEWS

2053 Identification of genes associated with gall bladder cell carcinogenesis: Implications in targeted therapy of gall bladder cancer

Ghosh I, Dey Ghosh R, Mukhopadhyay S

ORIGINAL ARTICLE

Clinical and Translational Research

2064 Transient receptor potential-related risk model predicts prognosis of hepatocellular carcinoma patients Mei XC, Chen Q, Zuo S

Retrospective Cohort Study

2077 Cohort study to assess geographical variation in cholangiocarcinoma treatment in England Jose S, Zalin-Miller A, Knott C, Paley L, Tataru D, Morement H, Toledano MB, Khan SA

Retrospective Study

2093 Effect of ultrasound-guided lumbar square muscle block on stress response in patients undergoing radical gastric cancer surgery

Wang XR, Xu DD, Guo MJ, Wang YX, Zhang M, Zhu DX

- 2101 Application of remimazolam transversus abdominis plane block in gastrointestinal tumor surgery Liu J, Tian JM, Liu GZ, Sun JN, Gao PF, Zhang YQ, Yue XQ
- 2111 The efficacy of full-thickness endoscopic resection of subepithelial tumors in the gastric cardia Xu EP, Qi ZP, Li B, Ren Z, Cai MY, Cai SL, Lyv ZT, Chen ZH, Liu JY, Shi Q, Zhong YS

Basic Study

2120 Hsa_circ_0136666 mediates the antitumor effect of curcumin in colorectal carcinoma by regulating CXCL1 via miR-1301-3p

Chen S, Li W, Ning CG, Wang F, Wang LX, Liao C, Sun F

Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ 2138 and CD8+ T cell-mediated antitumor immune responses

Zhang XS, Zhou HC, Wei P, Chen L, Ma WH, Ding L, Liang SC, Chen BD



World Journal of Gastrointestinal Oncology Contents Monthly Volume 15 Number 12 December 15, 2023 2150 Association between heat shock factor protein 4 methylation and colorectal cancer risk and potential molecular mechanisms: A bioinformatics study Zhang WJ, Yue KL, Wang JZ, Zhang Y 2169 Evaluating the causal relationship between human blood metabolites and gastroesophageal reflux disease Hu JY, Lv M, Zhang KL, Qiao XY, Wang YX, Wang FY 2185 Paired-related homeobox 1 induces epithelial-mesenchymal transition in oesophageal squamous cancer Guo JB, Du M, Wang B, Zhong L, Fu ZX, Wei JL **META-ANALYSIS** Intensive follow-up vs conventional follow-up for patients with non-metastatic colorectal cancer treated 2197 with curative intent: A meta-analysis Cui LL, Cui SQ, Qu Z, Ren ZQ 2212 Prognostic value of T cell immunoglobulin and mucin-domain containing-3 expression in upper gastrointestinal tract tumors: A meta-analysis Yan JJ, Liu BB, Yang Y, Liu MR, Wang H, Deng ZQ, Zhang ZW

2225 Association of MBOAT7 rs641738 polymorphism with hepatocellular carcinoma susceptibility: A systematic review and meta-analysis

Lai M, Qin YL, Jin QY, Chen WJ, Hu J

CASE REPORT

2237 Conversion immunotherapy for deficient mismatch repair locally unresectable colon cancer: A case report Sun Z, Liu H, Zhang GN, Xiao Y



Contents

Monthly Volume 15 Number 12 December 15, 2023

ABOUT COVER

Editorial Board Member of World Journal of Gastrointestinal Oncology, Luigi Marano, MD, PhD, Professor, Department of Medicine, Academy of Medical and Social Applied Sciences-AMiSNS: Akademia Medycznych i Spolecznych Nauk Stosowanych-2 Lotnicza Street, Elbląg 82-300, Poland. l.marano@amisns.edu.pl

AIMS AND SCOPE

The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGO as 3.0; IF without journal self cites: 2.9; 5-vear IF: 3.0; Journal Citation Indicator: 0.49; Ranking: 157 among 241 journals in oncology; Quartile category: Q3; Ranking: 58 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2022 is 4.1 and Scopus CiteScore rank 2022: Gastroenterology is 71/149; Oncology is 197/366.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Xiang-Di Zhang; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS	
World Journal of Gastrointestinal Oncology	https://www.wignet.com/bpg/gerinfo/204	
,	-I. () () () () () () () () () (
ISSN	GUIDELINES FOR ETHICS DOCUMENTS	
ISSN 1948-5204 (online)	https://www.wjgnet.com/bpg/GerInfo/287	
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH	
February 15, 2009	https://www.wjgnet.com/bpg/gerinfo/240	
FREQUENCY	PUBLICATION ETHICS	
Monthly	https://www.wjgnet.com/bpg/GerInfo/288	
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT	
Monjur Ahmed, Florin Burada	https://www.wjgnet.com/bpg/gerinfo/208	
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE	
https://www.wjgnet.com/1948-5204/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242	
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS	
December 15, 2023	https://www.wjgnet.com/bpg/GerInfo/239	
COPYRIGHT	ONLINE SUBMISSION	
© 2023 Baishideng Publishing Group Inc	https://www.f6publishing.com	

© 2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



 \mathcal{O} WU

World Journal of **Gastrointestinal** Oncology

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Oncol 2023 December 15; 15(12): 2138-2149

DOI: 10.4251/wjgo.v15.i12.2138

ISSN 1948-5204 (online)

ORIGINAL ARTICLE

Basic Study Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cellmediated antitumor immune responses

Xu-Sheng Zhang, Hong-Cai Zhou, Peng Wei, Long Chen, Wei-Hu Ma, Lin Ding, Shi-Cai Liang, Ben-Dong Chen

Specialty type: Oncology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B Grade C (Good): C Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Arvanitakis K, Greece; Cuno C, Spain

Received: September 5, 2023 Peer-review started: September 5, 2023 First decision: September 15, 2023 Revised: October 9, 2023 Accepted: November 8, 2023 Article in press: November 8, 2023 Published online: December 15, 2023



Xu-Sheng Zhang, Hong-Cai Zhou, Peng Wei, Long Chen, Wei-Hu Ma, Lin Ding, Shi-Cai Liang, School of Clinical Medicine, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China

Ben-Dong Chen, Department of Hepatobiliary Surgery, The General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China

Ben-Dong Chen, Hepatobiliary Pancreatic Surgical, Ningxia Hepatobiliary Pancreatic Surgical Diseases Clinical Research Center, Yinchuan 750004, Ningxia Hui Autonomous Region, China

Corresponding author: Ben-Dong Chen, MD, Doctor, Department of Hepatobiliary Surgery, The General Hospital of Ningxia Medical University, No. 804 Shengli Street, Yinchuan 750004, Ningxia Hui Autonomous Region, China. bendong8511@nyfy.com.cn

Abstract

BACKGROUND

Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) are beneficial to the resumption of anti-tumor immunity response and hold extreme potential as efficient therapies for certain malignancies. However, ICIs with a single target exhibit poor overall response rate in hepatocellular carcinoma (HCC) patients due to the complex pathological mechanisms of HCC.

AIM

To investigate the effects of combined TIM-3 and PD-1 blockade on tumor development in an HCC mouse model, aiming to identify more effective immunotherapies and provide more treatment options for HCC patients.

METHODS

The levels of PD-1 and TIM-3 on CD4+ and CD8+ T cells from tumor tissues, ascites, and matched adjacent tissues from HCC patients were determined with flow cytometry. An HCC xenograft mouse model was established and treated with anti-TIM-3 monoclonal antibody (mAb) and/or anti-PD-1 mAb. Tumor growth in each group was measured. Hematoxylin and eosin staining and immunohistochemical staining were used to evaluate T cell infiltration in tumors.



The percentage of CD4+ and CD8+ T cells in tissue samples from mice was tested with flow cytometry. The percentages of PD-1+CD8+, TIM-3+CD8+, and PD-1+TIM-3+ CD8+ T cells was accessed by flow cytometry. The levels of the cytokines including tumor necrosis factor alpha (TNF- α), interferon- γ (IFN- γ), interleukin (IL)-6, and IL-10 in tumor tissues were gauged with enzyme-linked immunosorbent assay kits.

RESULTS

We confirmed that PD-1 and TIM-3 expression was substantially upregulated in CD4+ and CD8+ T cells isolated from tumor tissues and ascites of HCC patients. TIM-3 mAb and PD-1 mAb treatment both reduced tumor volume and weight, while combined blockade had more substantial anti-tumor effects than individual treatment. Then we showed that combined therapy increased T cell infiltration into tumor tissues, and downregulated PD-1 and TIM-3 expression on CD8+ T cells in tumor tissues. Moreover, combined treatment facilitated the production of T cell effector cytokines TNF- α and IFN- γ , and reduced the production of immunosuppressive cytokines IL-10 and IL-6 in tumor tissues. Thus, we implicated that combined blockade could ameliorate T cell exhaustion in HCC mouse model.

CONCLUSION

Combined TIM-3 and PD-1 blockade restrains HCC development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses.

Key Words: Hepatocellular carcinoma; T cell immunoglobulin and mucin domain-containing protein 3; Programmed cell death protein 1; CD4+ T cells; CD8+ T cells

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This study investigated the effects of combined blockade of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) and programmed cell death protein 1 (PD-1) on tumor development in a hepatocellular carcinoma (HCC) mouse model. We showed that combined TIM-3 and PD-1 blockade had more substantial inhibitory effects on tumor growth in mice compared with individual blockade. The combined therapy increased T cell infiltration and ameliorated CD4+ and CD8+ T cell exhaustion in HCC mouse model. Our findings proposed an effective immunotherapy and may provide more treatment options for HCC patients.

Citation: Zhang XS, Zhou HC, Wei P, Chen L, Ma WH, Ding L, Liang SC, Chen BD. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses. World J Gastrointest Oncol 2023; 15(12): 2138-2149

URL: https://www.wjgnet.com/1948-5204/full/v15/i12/2138.htm DOI: https://dx.doi.org/10.4251/wjgo.v15.i12.2138

INTRODUCTION

Hepatocellular carcinoma (HCC) is the fourth most intractable tumor in clinic worldwide[1]. The majority of HCC patients have advanced-stage diagnoses, which are frequently accompanied by distant metastases [2,3]. Surgical resection, chemotherapy and local ablative therapy are three conventional methods used in clinical HCC treatment, but which have limited effects on advanced HCC patients, such as tumor recurrence, drug resistance, and unsatisfactory survival rate and prognosis[4-6]. It's general known that the aggressive tumor progression is intimately related to immune escape mediated by multiple mechanisms^[7,8]. Recently, multiple novel immune therapies, such as blockade of immune checkpoints and adoptive T-cell transfer, have been identified as efficient and safe therapies for malignant tumors with long-term survival and acceptable toxicity, which have attracted more attention and provide novel directions for HCC treatment[9,10]. Therefore, it's essential to identify more effective immunotherapies and provide more treatment options to achieve satisfactory survival rate and prognosis for HCC patients.

The tumor microenvironment has been frequently studied in cancer research. It's generally known that tumor-infiltrating lymphocytes (TILs) contribute to anti-tumor immunity and affect the cancer progression of patients[11,12]. Changes in TIL numbers, localization and phenotypes are indispensable indicators of cancer progression and immunotherapy efficacy[13]. Among them, T cells are essential for identifying and destroying tumor cells. The increased T cell infiltration is a positive prognostic indicator in HCC immunotherapy management[14]. Cytotoxic CD8+ T cells can eliminate malignant cancer cells and is an important defense line for anti-tumor immunity[15]. Additionally, there is evidence that CD4+ T cells can eliminate malignant cancer cells[16]. Nevertheless, persistent tumor antigen stimulation can cause T cell exhaustion and loss of function, resulting in tumor immune escape[17].

It is generally recognized that exhausted T cells are accompanied by frequent expression of various co-inhibitory receptors, such as programmed cell death protein 1 (PD-1), T cell immunoglobulin and mucin domain-containing protein



Bishidena® WJGO | https://www.wjgnet.com

3 (TIM-3)[18]. These receptors can inhibit T cell function by interacting with their specific ligands, which are also called immune checkpoints. It has been previously revealed that blockage of immune checkpoints is beneficial to the resumption of anti-tumor immunity response and holds extreme potential as an efficient method for certain malignancies including advanced melanoma and lung cancer[19,20]. Currently, immune checkpoint inhibitors (ICIs) targeting PD-1 exhibits encouraging outcomes for HCC immunotherapy in clinic[21]. These inhibitors are essentially monoclonal antibodies (mAb) and have received increased attention. However, due to the complex pathological mechanisms of HCC, ICIs with a single target exhibit poor overall response rate in HCC patients^[22]. Therefore, combination therapy with more targets may be a better option to achieve better clinical outcomes.

Given the limited studies study about TIM-3 blockade in HCC, our study first characterized the expression of PD-1 and TIM-3 in CD4+ and CD8+ T cells from clinical HCC samples. Then we focused on investigating the effects of combined blockade of TIM-3 and PD-1 on T cell immunological function and cancer development in an HCC mouse model.

MATERIALS AND METHODS

Clinical specimens

We recruited 20 HCC patients (12 males and 8 females; age 63.7 ± 7.3 years) at the General Hospital of Ningxia Medical University between February 2022 and May 2022. Tumor tissues, paired non-tumor adjacent tissues, and malignant ascites were collected during surgery. None of the patients received chemoradiotherapy or immunotherapy before surgery. This study was conducted with the approval of the Ethics Committee of the General Hospital of Ningxia Medical University. All participants provided clinical specimens and signed the informed consent forms (Table 1).

Animals and cell line

Healthy male BALB/c nude mice (18-20 g) were obtained from the experimental animal center of Ningxia Medical University. They were maintained in standard laboratory environment with a 12 h light/dark cycle, 22-25 °C temperature, 55%-60% humidity, and free access to food and water. HepG2 cells were obtained from ATCC (Manassas, VA, United States), and cultured in DMEM containing 10% foetal bovine serum and 1% antibiotics at 37 °C in 5% CO₂.

Isolation of mononuclear cells from tissues and ascites

Mononuclear cell suspensions from tumor and adjacent tissues were obtained according to previously described method [23,24]. In general, tumor and adjacent tissues were mechanically fragmented and digested in RPMI 1640 with 1 mg/mL collagenase IV, 0.04 mg/mL DNAse I, and 0.4 mg/mL hyaluronidase for 1 h at 37 °C. The obtained mixture was filtered using cell strainers with a 70 µm pore size to acquire cells. Moreover, ascites supernatant was collected using a centrifuge set at 400 × g for 10 min. Afterwards, mononuclear cells in the tissue suspension and ascites were separated and collected by Ficoll density gradient centrifugation with Lymphoprep (Stemcell Technologies, Canada). Cells were then washed and resuspended in RPMI 1640.

Flow cytometry

The isolated mononuclear cells were stained with fluorescence-conjugated mAb in the dark at 4 °C for 20 min. The fluorescence-conjugated mAb provided by eBioscience (San Diego, United States) were as follows: Fluorescein isothiocyanate (FITC)-conjugated CD4, FITC-conjugated CD8, allophycocyanin-conjugated PD-1, phycoerythrinconjugated TIM-3, and the corresponding isotype controls. Flow cytometry was conducted with a flow cytometer (BD Biosciences, CA, United States). FlowJo software (Treestar, CA, United States) was used to analyze the data. Antigen expression is represented by the fluorescence intensity on dual-parameter scattergrams.

Animal studies

After acclimatization to the environment for one week, 4×10^5 HepG2 cells were subcutaneously injected into the right flank of mice. These model mice were divided into four treatment groups (n = 8 each group). Mice were administrated with immunoglobulin G (IgG) isotype control (100 µg), anti-TIM-3 mAb (100 µg) or/and anti-PD1 mAb (100 µg) in a volume of 200 µL via intraperitoneal injection twice a week for sustained 4 wk. These mAbs were all purchased from BioXcell (New Hampshire, United States). Tumor volume was calculated every week. Peripheral blood was collected before euthanasia and kept in an anticoagulant tube. Then tumor tissues, spleen, and thymus were completely separated and weight was recorded. All animal experiments in this study were approved by the Ethics Committee of the General Hospital of Ningxia Medical University.

Immune organ indices

The spleen or thymus index can roughly estimate the strength of immune function. They were calculated by the following equation: Spleen/thymus index (mg/g) = the weight of spleen/thymus (mg)/body weight (g).

Hematoxylin and eosin staining

Paraffin-embedded tissues were prepared and cut into 4 µm thick slices. Tissue slices were deparaffinized with xylene, dehydrated, and stained with hematoxylin and eosin (HE) solution. After cleaning and sealing with neutral resin, slices were photographed under light microscope.



Table 1 Patient characteristics		
Patient characteristics		n
Age (yr)	< 60	14
	≥ 60	6
Gender	Male	12
	Female	8
Pathologic stage	Stage I	4
	Stage II	12
	Stage III	4

Immunohistochemical staining

After deparaffinization with xylene and rehydration, 4 μ m paraffin-embedded tissue slices were mixed with sodium citrate solution and heated in a microwave oven, followed by adding 3% H₂O₂ for 10 min of inactivation. Thereafter, the slices were incubated with primary antibodies against CD4 (ab133616, Abcam) and CD8 (ab217344, Abcam) overnight at 4 °C, and secondary antibody for 1 h. Next, the slices were developed with a diaminobenzidine immunohistochemistry color development kit (Beyotime, Shanghai, China). Finally, positive staining was imaged under a light microscope and analyzed with the ImageJ software (NIHB, Maryland, United States).

Mononuclear cell isolation

Cell supernatants from tumor tissues were obtained according to the method we mentioned above. Moreover, the obtained spleens were softly pulverized by filtering through a 200-gauge steel mesh, and digested in FACS lysis solution. The mixture was centrifuged and washed with phosphate buffered saline. Then, mononuclear cells in tumor and spleen tissue suspensions were obtained by density gradient centrifugation. Peripheral mononuclear cells were isolated with mouse lymphocyte separation medium (Solarbio, Shanghai, China).

Cytokine level detection

Tumor tissues were lysed, and the supernatant was collected by centrifugation. The levels of the cytokines including tumor necrosis factor alpha (TNF- α), interferon- γ (IFN- γ), interleukin (IL)-6, and IL-10 in tumor tissues were gauged with corresponding enzyme-linked immunosorbent assay kits.

Statistical analysis

Data from at least triplicate independent experiments were presented as mean \pm SD and analyzed with SPSS 22.0 software. Student's *t*-test or one-way analysis of variance (ANOVA) was used to analyze comparisons among groups. *P* < 0.05 was considered statistically significant.

RESULTS

PD-1 and TIM-3 were upregulated in T cells from HCC patients

We first determined PD-1 and TIM-3 levels on CD4+ and CD8+ T cells from HCC patients by flow cytometry. As exhibited in Figures 1A-D, compared with matched adjacent tissues, they were both conspicuously upregulated in CD4+ and CD8+ T cells from tumor tissues. Our results also implied that PD-1 and TIM-3 were also highly expressed in conveniently available clinical ascites samples. Afterwards, we observed that their expression on T cells in tumor tissues was positively correlated with that in ascites (Figures 1E-H).

Combined TIM-3 and PD-1 blockade restrained xenograft tumor growth in mice

Anti-PD-1 agents have been used in clinic for HCC treatment[25,26]. However, the effects of anti-TIM-3 agents have not been fully clarified. We next determined the anti-tumor activities of anti-TIM-3 mAb, anti-PD-1 mAb and their combination in HCC. A xenograft mouse model of HCC was established. Tumor images were presented in Figure 2A, and it was observed that TIM-3 and PD-1 mAb treatment both reduced tumor volume (Figure 2B) and weight (Figure 2C) compared with IgG treatment. Moreover, combined blockade had more substantial anti-tumor effects than individual treatment. In addition, the spleen index (Figure 2D) was obviously elevated and the thymus index (Figure 2E) was decreased in model mice, indicating the impaired immunity in model mice. However, individual or combination treatment substantially reduced the spleen index and increased the thymus index in mice, while the effects of combination treatment were more significant. Our results illustrated that combined blockade restrained xenograft tumor growth and ameliorated the tumor immunosuppressive microenvironment in mice.



DOI: 10.4251/wjgo.v15.i12.2138 Copyright ©The Author(s) 2023.

Figure 1 Programmed cell death protein 1 and T cell immunoglobulin and mucin domain-containing protein 3 were upregulated in CD4⁺ and CD8⁺ T cells isolated from hepatocellular carcinoma patients. Mononuclear cells were isolated from tumor tissues, ascites, and matched adjacent tissues of hepatocellular carcinoma (HCC) patients. A and B: Programmed cell death protein 1 (PD-1) (A) and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) (B) expression on CD4+ T cells in tumor tissues, ascites, and matched adjacent tissues of HCC patients (n = 20) was assessed with flow cytometry; C and D: PD-1 (C) and TIM-3 (D) expression on CD4+ T cells in tumor tissues, ascites, and matched adjacent tissues of HCC patients (n = 20) was assessed with flow cytometry; E and F: PD-1 expression on CD4+ (E) cells and CD8+ (F) T cells in tumor tissues was positively correlated with that in ascites; G and H: TIM-3 expression on CD4+ cells and CD8+ T cells in tumor tissues was positively correlated with that in ascites; G and H: TIM-3 expression on CD4+ cells and CD8+ T cells in tumor tissues was positively correlated with that in ascites. Data from at least three independent experiments were presented as mean \pm SD. ^aP < 0.01, tumor group compared with the adjacent group; ^bP < 0.01, ascites group compared with the adjacent group. PD-1: Programmed cell death protein 1; TIM-3: T cell immunoglobulin and mucin domain-containing protein 3.

Combined TIM-3 and PD-1 blockade activated CD4+ and CD8+ T cell infiltration into tumor tissues

We next investigated the effects of combined blockade on TILs in tumor microenvironment. HE staining illustrated that combined blockade alleviated the apoptotic characteristics of TILs and increased the number of TILs. Particularly, these changes were more obvious in the combination treatment group (Figure 3A). Additionally, immunohistochemical staining indicated that combined blockade improved the number of CD4+ (Figures 3B and C) and CD8+ (Figures 3D and E) T cells in mice. Our results revealed that combined blockade could prominently activate T cell infiltration.

Combined TIM-3 and PD-1 blockade increased the percentage of CD4+ and CD8+ T cells in mice

The main immunosuppressive mechanism of cancer cells is intimately related to CD4+ and CD8+ T cells[15,16]. The percentage of CD4+ and CD8+ T cells in tumor tissues, peripheral blood and spleen was then tested with flow cytometry. As expected, TIM-3 and PD-1 blockade prominently increased the percentage of CD4+ (Figures 4A-C) and CD8+ (Figures 4D-F) T cells in all collected samples of mice, especially the combined group, which exhibited more significant alterations. Therefore, we proposed that combined blockade could increase the percentage of CD4+ and CD8+ T cells and improve anti-tumor immune responses.

Zaishideng® WJGO | https://www.wjgnet.com



Figure 2 Combined T cell immunoglobulin and mucin domain-containing protein 3 and programmed cell death protein 1 blockade restrained xenograft tumor growth in mice. A xenograft mouse model of hepatocellular carcinoma was established by subcutaneously injecting HepG2 cells into mice. These model mice were treated with immunoglobulin G (IgG) isotype control (IgG group; n = 8), anti-T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) monoclonal antibody (mAb) (TIM-3 mAb group; n = 8), anti-programmed cell death protein 1 (PD-1) mAb (PD-1 mAb group; n = 8), and combined anti-TIM-3 mAb and anti-PD-1 mAb (TIM-3 mAb + PD-1 mAb group; n = 8) for 4 wk. A: Tumor images in the four groups; B: Tumor volume; C: Tumor weight of mice in the four groups were recorded; D and E: The spleen index (D) and thymus index (E) were determined after euthanasia. Data from at least three independent experiments were presented as mean ± SD. ^dP < 0.01, compared with healthy control mice; ^aP < 0.01, ^bP < 0.01, ^cP < 0.01, compared with the immunoglobulin G isotype control group. PD-1: Programmed cell death protein 1; TIM-3: T cell immunoglobulin and mucin domain-containing protein 3; IgG: Immunoglobulin G; mAb: Monoclonal antibody.

Combined TIM-3 and PD-1 blockade ameliorated T cell exhaustion

T cell exhaustion is a vital immune escape mechanism in tumor microenvironment, and is accompanied by increased coinhibitory receptor expression[27,28]. Therefore, we determined the roles of combined blockade in T cell exhaustion phenotypes in a xenograft mouse model. PD-1+CD8+ and TIM-3+CD8+ T cells in tumor tissues were assessed. Our results clearly indicated that PD-1 blockade prominently decreased PD-1+CD8+ T cell levels (Figures 5A and D) compared with IgG treatment, while anti-TIM-3 blockade restrained TIM-3+CD8+ T cell numbers (Figures 5B and E) in tumor tissues. Moreover, combined treatment simultaneously reduced PD-1+CD8+ T cell and TIM-3+CD8+ T cell numbers. Additionally, combined blockade obviously inhibited PD-1+TIM-3+CD8+ T cell numbers (Figures 5C and F). Collectively, our results suggested that combined blockade could ameliorate the exhausted CD8+ T cell phenotype in the immunosuppressive microenvironment of HCC.

Combined TIM-3 and PD-1 blockade affected immune effector chemokines in mice

Solvent cytokines provide another crucial distinctive marker for T cell exhaustion. We detected the levels of critical T cell effector cytokines, IFN- γ and TNF- α , and immunosuppressive cytokines, IL-10 and IL-6 in tumor tissues of all groups of mice. It was revealed that the individual blockade of TIM-3 and PD-1 prominently facilitated IFN- γ and TNF- α production (Figures 6A and B), and reduced IL-10 and IL-6 levels (Figures 6C and D). Importantly, such changes were more obvious in the combined group. Thus, the above results highlighted the crucial effect of combined blockade on restoring exhausted CD8+T cell mediated anti-tumor capability.

DISCUSSION

To date, multiple effective and safe immunotherapies have achieved gratifying survival rate and prognosis for HCC patients. which have attracted more attention and provide novel directions for HCC treatment. It's generally identified



Zaishidena® WJGO | https://www.wjgnet.com

Zhang XS et al. TIM-3 and PD-1 blockade restrains HCC



Figure 3 Combined blockade activated CD4⁺ and CD8⁺ T cell infiltration into tumor tissues. A: The infiltration of tumor-infiltrating lymphocytes into tumor tissues was evaluated with hematoxylin and eosin staining; B-E: Immunohistochemical staining was employed to assess CD4+ (B, C) and CD8+ (D, E) T cell

Saishideng® WJGO | https://www.wjgnet.com

December 15, 2023 Volume 15 Issue 12

numbers in tumor tissues. Data from at least three independent experiments were presented as mean \pm SD. ^aP < 0.01, ^bP < 0.01, ^cP < 0.01, compared with the immunoglobulin G isotype control group. PD-1: Programmed cell death protein 1; TIM-3: T cell immunoglobulin and mucin domain-containing protein 3; IgG: Immunoglobulin G; mAb: Monoclonal antibody.



Figure 4 Combined blockade increased the percentage of CD4⁺ and CD8⁺ T cells in mice. A-C: The percentage of CD4⁺ T cells in tumor tissues (A), peripheral blood (B) and spleen (C) of mice in four groups was tested with flow cytometry. E and F: The percentage of CD8⁺ T cells in (D) tumor tissues, peripheral blood (E) and spleen (F) of mice in four groups was tested with flow cytometry. Data from at least three independent experiments were presented as mean \pm SD. ^a*P* < 0.01, ^b*P* < 0.01, ^c*P* < 0.01, compared with the immunoglobulin G isotype control group. PD-1: Programmed cell death protein 1; TIM-3: T cell immunoglobulin and mucin domain-containing protein 3; IgG: Immunoglobulin G; mAb: Monoclonal antibody.

that increased TIL infiltration in tumor microenvironment has consistently been linked to improved outcomes for HCC patients in clinic[14]. The ability of tumor specific effector CD4+ and CD8+ T cells is intimately associated with their numbers, localization, and phenotype[15,16]. T cells are essential for identifying and destroying tumor cells. However, persistent tumor antigen stimulation can cause T cell exhaustion and loss of function, resulting in tumor immune escape [17]. Meanwhile, it has been reported that increased co-inhibitory receptor expression induces T cell exhaustion phenotype, leading to T cell immunodeficiency[18]. Thus, restoring T cell functions through blockade of immune checkpoints continues to be a dominant approach for cancer treatment. To date, advanced development of ICIs has been achieved, and multiple ICIs targeting PD-1 have been applied for HCC patients[25,26]. However, PD-1/PD-L1 is just one of numerous complex elements of anti-tumor immunity, and only blockage of PD-1 has the limitation of unsatisfactory curative effects and drug resistance. Therefore, the combination of multiple ICIs may have additive effects and become a better option to treat advanced HCC.

TIM-3 was identified as a promising immune checkpoint molecule. The therapeutic method of TIM-3 blockade has been studied in multiple human tumor immunotherapies, especially in combination with other immune checkpoints[29]. It has been previously found that multiple co-inhibitory receptors, including PD-1 and TIM-3, are prominently upregulated on CD4+ and CD8+ T cells from tumor tissues of HCC patients[24]. Moreover, TIM-3 and PD-1 positive CD8+ T cells were indicated to be related to adverse outcomes for HCC[23]. However, TIM-3 blockade is relatively poorly studied in HCC. Our study first collected clinical samples from HCC patients, and confirmed that PD-1 and TIM-3 expression was substantially upregulated in CD4+ and CD8+ T cells isolated from tumor tissues and ascites compared with matched adjacent tissues. Ascites are conveniently available clinical samples, and our results support the adoption of ascites as an alternative site for TIM-3 recognition and patient stratification to manage TIM-3 blockers.

A previous meta-analysis revealed that TIM-3 upregulation was linked to adverse prognosis in individuals with various cancers, and they proposed that TIM-3 might be a dominant target[30]. Notably, TIM-3 blockage in combination with radiation could improve anti-tumor efficacy in an HCC mouse model[31]. Our study suggested that individual TIM-3 mAb and PD-1 mAb treatment both reduced tumor volume and weight, while combined blockade had more substantial tumor suppressive effect than individual treatment. In addition, the combination therapy also reduced the spleen index and increased the thymus index in mice, indicating the improvement in the immunosuppressive tumor microenvir-

Zaishideng® WJGO | https://www.wjgnet.com



Figure 5 Combined blockade ameliorated T cell exhaustion. A and D: The percentages of programmed cell death protein 1 (PD-1)+CD8+ T cells; B and E: T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3)+CD8+ T cells; C and F: PD-1+TIM-3+CD8+ T cells in the tumor tissues of mice in the four groups was assessed with flow cytometry. Data from at least three independent experiments were presented as mean ± SD. $^{a}P < 0.01$, $^{b}P < 0.01$, $^{c}P < 0.01$, compared with the immunoglobulin G isotype control group. PD-1: Programmed cell death protein 1; TIM-3: T cell immunoglobulin and mucin domain-containing protein 3; IgG: Immunoglobulin G; mAb: Monoclonal antibody.

onment. More importantly, combined blockade prominently upregulated CD4+ and CD8+ T cells and activated cell infiltration into tumor tissues. Additionally, our results showed that combined blockade can simultaneously downregulate PD-1 and TIM-3 expression on CD8+ T cells. Likewise, PD-1+TIM-3+ CD8+ T cell numbers in tumor tissues were obviously reduced by combination therapy. Meanwhile, combined blockade also facilitated IFN- γ and TNF- α production, and reduced the production of IL-10 and IL-6 in tumor tissues. Therefore, we implicated that combined blockade could ameliorate T cell exhaustion in HCC model mice.

CONCLUSION

Taken together, our study proposed that the combined blockade of TIM-3 and PD-1 had an additive anti-tumor effect on an HCC mouse model compared with individual treatment. Combined therapy improved anti-tumor immune responses in HCC mouse model by increasing CD4+ and CD8+ T cell infiltration, down-regulating the co-inhibitory receptors TIM-3 and PD-1, and ameliorating T cell exhaustion. We hope that our findings will benefit to the clinical treatment of HCC.

Raishideng® WJGO https://www.wjgnet.com



DOI: 10.4251/wjgo.v15.i12.2138 Copyright ©The Author(s) 2023.

Figure 6 Combined blockade of T cell immunoglobulin and mucin domain-containing protein 3 and programmed cell death protein 1 affected immune effector chemokines in mice. A-D: The levels of T cell effector cytokines interferon-y (A) and (B) tumor necrosis factor-a, and immunosuppressive cytokines interleukin (IL)-10 (C) and IL-6 (D) in tumor tissues of mice in four groups were gauged with enzyme-linked immunosorbent assay kits. Data from at least three independent experiments were presented as mean ± SD. *P < 0.01, *P < 0.01, *P < 0.01, compared with the immunoglobulin G isotype control group. PD-1: Programmed cell death protein 1; TIM-3: T cell immunoglobulin and mucin domain-containing protein 3; IgG: Immunoglobulin G. IL: Interleukin; TNF-α: Tumor necrosis factor-α; IFN-γ: Interferon-γ; mAb: Monoclonal antibody.

ARTICLE HIGHLIGHTS

Research background

Hepatocellular carcinoma (HCC) is the fourth intractable tumors in clinic worldwide. Recently, immune checkpoint inhibitors (ICIs), a novel immune therapy, has been identified as an efficient and safe therapy for malignant tumors, which have attracted more attention and give novel directions for HCC treatment.

Research motivation

ICIs targeting programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) are benefit to the resume of anti-tumor immunity response and hold extreme potential as efficient therapies for certain malignancies. Given the complex pathological mechanisms of HCC, ICIs with a single target exhibit poor overall response rate in HCC patients. Therefore, it's of great significance to identify more effective immunotherapies and provide more treatment options to achieve gratifying survival rate and prognosis for HCC patients.

Research objectives

This study investigated the effects of combined TIM-3 and PD-1 blockade on tumor development in an HCC mouse model, aiming to identify more effective immunotherapies and provide more treatment options for HCC patients.

Research methods

We first detected the levels of PD-1 CD4+, PD-1 CD8+, TIM-3 CD4+, and TIM-3 CD8+ in tumor tissues, ascites, and matched adjacent tissues from HCC patients. Next, we investigated the effects of combined and individual blockage of TIM-3 and PD-1 on an HCC xenograft mouse model. Tumor growth and CD4+ and CD8+ T cell-mediated antitumor immune responses were assessed.

Research results

PD-1 and TIM-3 expression was upregulated in CD4+ and CD8+ T cells isolated from tumor tissues and ascites of HCC patients. TIM-3 mAb and PD-1 mAb treatment both reduced tumor volume and weight, while combined blockade had more substantial anti-tumor effects compared with individual treatment. The combined therapy increased T cell infiltration into tumor tissues, and ameliorated CD4+ and CD8+ T cell exhaustion in HCC mouse model.

Research conclusions

Combined TIM-3 and PD-1 blockage has more substantial anti-tumor effects compared with individual blockage. Combined TIM-3 and PD-1 blockage restrains HCC development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses.



Research perspectives

We need to explore the effects of combination of multiple ICIs to provide better options for HCC treatment.

FOOTNOTES

Co-first authors: Xu-Sheng Zhang and Peng Wei.

Author contributions: Zhang XS, Wei P, and Liang SC were responsible for research design; Zhou HC, Peng Wei, and Long Chen contributed to the conducting the experiments; Zhang XS, Ding L, Chen BD, and Liang SC involved in the data acquisition; Chen L, Ma WH, and Ding L participated in the data analysis; Zhou HC, Ma WH, and Chen BD wrote the manuscript; and all the authors have contributed to the completion of this paper.

Supported by the First-Class Discipline Construction Founded Project of Ningxia Medical University and the School of Clinical Medicine, No 2020008

Institutional review board statement: This study was conducted with the approval of the Ethics Committee of the General Hospital of Ningxia Medical University. All participants provided clinical specimens and signed the informed consent forms.

Institutional animal care and use committee statement: All animal care and experimental procedures were approved by the Ethics Committee of the General Hospital of Ningxia Medical University.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Data sharing statement: All the data obtained in the current study were available from the corresponding authors on reasonable request.

ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Ben-Dong Chen 0009-0007-9960-1146.

S-Editor: Wang JJ L-Editor: A P-Fditor: Y11 HG

REFERENCES

- 1 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25: 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550]
- Zhang Y, Liu Z, Ji K, Li X, Wang C, Ren Z, Liu Y, Chen X, Han X, Meng L, Li L, Li Z. Clinical Application Value of Circulating Cell-free 2 DNA in Hepatocellular Carcinoma. Front Mol Biosci 2021; 8: 736330 [PMID: 34660697 DOI: 10.3389/fmolb.2021.736330]
- Li S, Wang P, Qiu J, Xie Y, Yin D, Deng K. Comparison of IDEAL-IQ and IVIM-DWI for Differentiating between Alpha Fetoprotein-3 Negative Hepatocellular Carcinoma and Focal Nodular Hyperplasia. Oncologie 2022; 24: 1-12 [DOI: 10.32604/oncologie.2022.022815]
- Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med 2021; 15: 155-169 4 [PMID: 33754281 DOI: 10.1007/s11684-021-0848-3]
- Wang K, Wang C, Jiang H, Zhang Y, Lin W, Mo J, Jin C. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where 5 We Are and Where to Go. Front Immunol 2021; 12: 792781 [PMID: 34975896 DOI: 10.3389/fimmu.2021.792781]
- Yan D, Li C, Zhou Y, Yan X, Zhi W, Qian H, Han Y. Exploration of Combinational Therapeutic Strategies for HCC Based on TCGA HCC 6 Database. Oncologie 2023; 24 [DOI: 10.32604/oncologie.2022.020357]
- Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, Li Y, Jiang X. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future 7 Prospects. Front Immunol 2021; 12: 765101 [PMID: 34675942 DOI: 10.3389/fimmu.2021.765101]
- Shu X, Wang Q, Wu Q. The Eph/Ephrin System in Hepatocellular Carcinoma: Functional Roles and Potential Therapeutic Targets. Oncologie 8 2022; 24: 427-439 [DOI: 10.32604/oncologie.2022.023248]
- 9 Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol 2019; 25: 3151-3167 [PMID: 31333308 DOI: 10.3748/wjg.v25.i25.3151]
- 10 Keilson JM, Knochelmann HM, Paulos CM, Kudchadkar RR, Lowe MC. The evolving landscape of immunotherapy in solid tumors. J Surg Oncol 2021; 123: 798-806 [PMID: 33595890 DOI: 10.1002/jso.26416]
- 11 Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol 2021; 18:



842-859 [PMID: 33139907 DOI: 10.1038/s41423-020-00565-9]

- Yu S, Lv H, Zhang J, Zhang H, Ju W, Jiang Y, Lin L. Heparanase/Syndecan-1 Axis Regulates the Grade of Liver Cancer and Proliferative 12 Ability of Hepatocellular Carcinoma Cells. Oncologie 2022; 24: 1-3 [DOI: 10.32604/oncologie.2022.024882]
- Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous 13 Melanoma. Front Immunol 2020; 11: 2105 [PMID: 33013886 DOI: 10.3389/fimmu.2020.02105]
- Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 2021; 11: 5365-5386 [PMID: 33859752 14 DOI: 10.7150/thno.58390]
- Reina-Campos M, Scharping NE, Goldrath AW. CD8(+) T cell metabolism in infection and cancer. Nat Rev Immunol 2021; 21: 718-738 15 [PMID: 33981085 DOI: 10.1038/s41577-021-00537-8]
- Oh DY, Fong L. Cytotoxic CD4(+) T cells in cancer: Expanding the immune effector toolbox. Immunity 2021; 54: 2701-2711 [PMID: 16 34910940 DOI: 10.1016/j.immuni.2021.11.015]
- Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, Schietinger A, Schumacher TN, 17 Schwartzberg PL, Sharpe AH, Speiser DE, Wherry EJ, Youngblood BA, Zehn D. Defining 'T cell exhaustion'. Nat Rev Immunol 2019; 19: 665-674 [PMID: 31570879 DOI: 10.1038/s41577-019-0221-9]
- 18 Ando M, Ito M, Srirat T, Kondo T, Yoshimura A. Memory T cell, exhaustion, and tumor immunity. Immunol Med 2020; 43: 1-9 [PMID: 31822213 DOI: 10.1080/25785826.2019.1698261]
- Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, Rosa F, Picasso V, Di Guardo L, Cimminiello C, Cavalieri S, Orgiano L, Tanda E, 19 Spano L, Falcone A, Queirolo P; Italian Melanoma Intergroup (IMI). Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget 2018; 9: 12452-12470 [PMID: 29552325 DOI: 10.18632/oncotarget.23746]
- 20 Saigi M, Alburquerque-Bejar JJ, Sanchez-Cespedes M. Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front. Oncogene 2019; 38: 5921-5932 [PMID: 31253869 DOI: 10.1038/s41388-019-0855-x]
- Wang J, Li J, Tang G, Tian Y, Su S, Li Y. Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma. Oncol Lett 21 2021; 21: 279 [PMID: 33732355 DOI: 10.3892/ol.2021.12540]
- 22 Li Q, Han J, Yang Y, Chen Y. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol 2022; 13: 1070961 [PMID: 36601120 DOI: 10.3389/fimmu.2022.1070961]
- Ma J, Zheng B, Goswami S, Meng L, Zhang D, Cao C, Li T, Zhu F, Ma L, Zhang Z, Zhang S, Duan M, Chen Q, Gao Q, Zhang X. PD1(Hi) 23 CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer 2019; 7: 331 [PMID: 31783783 DOI: 10.1186/s40425-019-0814-7]
- 24 Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology 2017; 153: 1107-1119.e10 [PMID: 28648905 DOI: 10.1053/j.gastro.2017.06.017]
- D'Alessio A, Rimassa L, Cortellini A, Pinato DJ. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. J 25 Hepatocell Carcinoma 2021; 8: 887-897 [PMID: 34386437 DOI: 10.2147/JHC.S284440]
- Chen Z, Lu X, Koral K. The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 26 2020; 14: 1017-1024 [PMID: 32762583 DOI: 10.1080/17474124.2020.1807939]
- Nagasaki J, Togashi Y. A variety of 'exhausted' T cells in the tumor microenvironment. Int Immunol 2022; 34: 563-570 [PMID: 35460561 27 DOI: 10.1093/intimm/dxac013]
- Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S. CD8(+) T Cell Exhaustion in Cancer. Front Immunol 2021; 12: 715234 28 [PMID: 34354714 DOI: 10.3389/fimmu.2021.715234]
- 29 Zhao L, Cheng S, Fan L, Zhang B, Xu S. TIM-3: An update on immunotherapy. Int Immunopharmacol 2021; 99: 107933 [PMID: 34224993 DOI: 10.1016/j.intimp.2021.107933]
- Qin S, Dong B, Yi M, Chu Q, Wu K. Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database 30 Evaluation. Front Oncol 2020; 10: 1288 [PMID: 32850398 DOI: 10.3389/fonc.2020.01288]
- Kim KJ, Lee HW, Seong J. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation 31 improves antitumor efficacy in murine hepatocellular carcinoma. J Gastroenterol Hepatol 2021; 36: 1357-1365 [PMID: 33217056 DOI: 10.1111/jgh.15319]



WJGO | https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

